1. Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial
- Author
-
Ostovaneh, Mohammad R, Makkar, Raj R, Ambale-Venkatesh, Bharath, Ascheim, Deborah, Chakravarty, Tarun, Henry, Timothy D, Kowalchuk, Glen, Aguirre, Frank V, Kereiakes, Dean J, Povsic, Thomas J, Schatz, Richard, Traverse, Jay H, Pogoda, Janice, Smith, Rachel D, Marbán, Linda, Marbán, Eduardo, and Lima, Joao AC
- Subjects
Heart Disease ,Clinical Trials and Supportive Activities ,Cardiovascular ,Clinical Research ,Heart Disease - Coronary Heart Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Female ,Follow-Up Studies ,Humans ,Magnetic Resonance Imaging ,Cine ,Male ,Middle Aged ,Myocardial Infarction ,Myocardium ,Myocytes ,Cardiac ,Retrospective Studies ,Stem Cell Transplantation ,Stroke Volume ,Transplantation ,Autologous ,Ventricular Dysfunction ,Left ,Ventricular Function ,Left ,MRI ,coronary artery disease ,epidemiology - Abstract
Most cell therapy trials failed to show an improvement in global left ventricular (LV) function measures after myocardial infarction (MI). Myocardial segments are heterogeneously impacted by MI. Global LV function indices are not able to detect the small treatment effects on segmental myocardial function which may have prognostic implications for cardiac events. We aimed to test the efficacy of allogeneic cardiosphere-derived cells (CDCs) for improving regional myocardial function and contractility. In this exploratory analysis of a randomised clinical trial, 142 patients with post-MI with LVEF
- Published
- 2021